Compound details
Lucuminoside
| Compound ID | CDAMM01453 |
|---|---|
| Common name | Lucuminoside | IUPAC name | 2-phenyl-2-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyacetonitrile |
| Molecular formula | C19H25NO10 |
| Retention time | 6.24 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 428.156 | Theoretical mz | 428.155 |
| Error | 1.46 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 7.264 |
| Inchi key | YYYCJNDALLBNEG-UHFFFAOYNA-N |
|---|---|
| Smiles | N#CC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C=3C=CC=CC3 |
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P29274 | ADORA2A | Adenosine A2a receptor | T77365 | SwissTargetPrediction |
| O43570 | CA12 | Carbonic anhydrase XII | T16987 | SwissTargetPrediction |
| Q16790 | CA9 | Carbonic anhydrase IX | T64567 | SwissTargetPrediction |
| P0DMS8 | ADORA3 | Adenosine A3 receptor | T36059 | SwissTargetPrediction |
| P00915 | CA1 | Carbonic anhydrase I | T13201 | SwissTargetPrediction |
| P00918 | CA2 | Carbonic anhydrase II | T20401 | SwissTargetPrediction |
| O43451 | MGAM | Maltase-glucoamylase | T92777 | SwissTargetPrediction |
| P43166 | CA7 | Carbonic anhydrase VII | T37541 | SwissTargetPrediction |
| P23280 | CA6 | Carbonic anhydrase VI | T06569 | SwissTargetPrediction |
| Q9ULX7 | CA14 | Carbonic anhydrase XIV | T31992 | SwissTargetPrediction |
| P22748 | CA4 | Carbonic anhydrase IV | T53378 | SwissTargetPrediction |
| P00491 | PNP | Purine nucleoside phosphorylase | T78198 | SwissTargetPrediction |
| Q04609 | FOLH1 | Glutamate carboxypeptidase II | T97071 | SwissTargetPrediction |
| P23975 | SLC6A2 | Norepinephrine transporter | T21945 | SwissTargetPrediction |
| P49841 | GSK3B | Glycogen synthase kinase-3 beta | T70977 | SwissTargetPrediction |
| P32320 | CDA | Cytidine deaminase (by homology) | T79027 | SwissTargetPrediction |
| P00813 | ADA | Adenosine deaminase | T03661 | SwissTargetPrediction |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SwissTargetPrediction and SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SwissTargetPrediction and SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SwissTargetPrediction and SEA |
| Q9Y251 | HPSE | Heparanase | T47623 | SwissTargetPrediction |
| P55263 | ADK | Adenosine kinase | T91661 | SwissTargetPrediction |
| Q99808 | SLC29A1 | Equilibrative nucleoside transporter 1 | T13491 | SwissTargetPrediction |
| P52789 | HK2 | Hexokinase type II | T96685 | SwissTargetPrediction |
| P31639 | SLC5A2 | Sodium/glucose cotransporter 2 | T30085 | SwissTargetPrediction |
| P35346 | SSTR5 | Somatostatin receptor 5 | T64830 | SwissTargetPrediction |
| P30874 | SSTR2 | Somatostatin receptor 2 | T53024 | SwissTargetPrediction |
| P31391 | SSTR4 | Somatostatin receptor 4 | T62974 | SwissTargetPrediction |
| P30872 | SSTR1 | Somatostatin receptor 1 | T16633 | SwissTargetPrediction |
| P32745 | SSTR3 | Somatostatin receptor 3 | T13644 | SwissTargetPrediction |
| P17931 | LGALS3 | Galectin-3 | T72038 | SwissTargetPrediction |
| P04746 | AMY2A | Pancreatic alpha-amylase | T86918 | SwissTargetPrediction and SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T77365 | DI0319 | Orthostatic hypotension | [ICD-11: BA21] | P29274 | ADORA2A |
| T77365 | DI0331 | Parkinsonism | [ICD-11: 8A00] | P29274 | ADORA2A |
| T77365 | DI0359 | Radionuclide imaging | [ICD-11: N.A.] | P29274 | ADORA2A |
| T16987 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | O43570 | CA12 |
| T16987 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | O43570 | CA12 |
| T64567 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | Q16790 | CA9 |
| T36059 | DI0351 | Psoriasis | [ICD-11: EA90] | P0DMS8 | ADORA3 |
| T36059 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P0DMS8 | ADORA3 |
| T13201 | DI0166 | Glaucoma | [ICD-11: 9C61] | P00915 | CA1 |
| T13201 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | P00915 | CA1 |
| T20401 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | P00918 | CA2 |
| T20401 | DI0137 | Essential hypertension | [ICD-11: BA00] | P00918 | CA2 |
| T20401 | DI0166 | Glaucoma | [ICD-11: 9C61] | P00918 | CA2 |
| T20401 | DI0175 | Heart failure | [ICD-11: BD10-BD1Z] | P00918 | CA2 |
| T20401 | DI0214 | Insomnia | [ICD-11: 7A00-7A0Z] | P00918 | CA2 |
| T20401 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | P00918 | CA2 |
| T92777 | DI0009 | Acute diabete complication | [ICD-11: 5A2Y] | O43451 | MGAM |
| T92777 | DI0201 | Inborn carbohydrate metabolism error | [ICD-11: 5C51] | O43451 | MGAM |
| T06569 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | P23280 | CA6 |
| T06569 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | P23280 | CA6 |
| T31992 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | Q9ULX7 | CA14 |
| T31992 | DI0204 | Inborn metabolism deficiency | [ICD-11: 5C50-5C59] | Q9ULX7 | CA14 |
| T53378 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | P22748 | CA4 |
| T53378 | DI0166 | Glaucoma | [ICD-11: 9C61] | P22748 | CA4 |
| T53378 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | P22748 | CA4 |
| T78198 | DI0120 | Diabetes mellitus | [ICD-11: 5A10] | P00491 | PNP |
| T78198 | DI0167 | Gout | [ICD-11: FA25] | P00491 | PNP |
| T78198 | DI0245 | Malignant haematopoietic neoplasm | [ICD-11: 2B33] | P00491 | PNP |
| T78198 | DI0283 | Mycosis fungoides | [ICD-11: 2B01] | P00491 | PNP |
| T78198 | DI0351 | Psoriasis | [ICD-11: EA90] | P00491 | PNP |
| T97071 | DI0122 | Diagnostic imaging | [ICD-11: N.A.] | Q04609 | FOLH1 |
| T97071 | DI0346 | Prostate cancer | [ICD-11: 2C82] | Q04609 | FOLH1 |
| T21945 | DI0013 | Acute pain | [ICD-11: MG31] | P23975 | SLC6A2 |
| T21945 | DI0040 | Attention deficit hyperactivity disorder | [ICD-11: 6A05] | P23975 | SLC6A2 |
| T21945 | DI0087 | Chronic pain | [ICD-11: MG30] | P23975 | SLC6A2 |
| T21945 | DI0101 | Corneal disease | [ICD-11: 9A76-9A78] | P23975 | SLC6A2 |
| T21945 | DI0117 | Depression | [ICD-11: 6A70-6A7Z] | P23975 | SLC6A2 |
| T21945 | DI0166 | Glaucoma | [ICD-11: 9C61] | P23975 | SLC6A2 |
| T21945 | DI0264 | Migraine | [ICD-11: 8A80] | P23975 | SLC6A2 |
| T21945 | DI0301 | Nicotine use disorder | [ICD-11: 6C4A] | P23975 | SLC6A2 |
| T21945 | DI0308 | Obesity | [ICD-11: 5B80-5B81] | P23975 | SLC6A2 |
| T21945 | DI0324 | Pain | [ICD-11: MG30-MG3Z] | P23975 | SLC6A2 |
| T21945 | DI0395 | Stomach cancer | [ICD-11: 2B72] | P23975 | SLC6A2 |
| T70977 | DI0288 | Myotonic disorder | [ICD-11: 8C71] | P49841 | GSK3B |
| T79027 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P32320 | CDA |
| T03661 | DI0016 | Adaptive immunity immunodeficiency | [ICD-11: 4A01] | P00813 | ADA |
| T03661 | DI0245 | Malignant haematopoietic neoplasm | [ICD-11: 2B33] | P00813 | ADA |
| T03661 | DI0249 | Mature B-cell leukaemia | [ICD-11: 2A82] | P00813 | ADA |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T47623 | DI0020 | African trypanosomiasis | [ICD-11: 1F51] | Q9Y251 | HPSE |
| T47623 | DI0310 | Ocular disease | [ICD-11: N.A.] | Q9Y251 | HPSE |
| T91661 | DI0134 | Epilepsy/seizure | [ICD-11: 8A61-8A6Z] | P55263 | ADK |
| T13491 | DI0030 | Angina pectoris | [ICD-11: BA40] | Q99808 | SLC29A1 |
| T96685 | DI0133 | Epidermal dysplasias | [ICD-11: EK90] | P52789 | HK2 |
| T30085 | DI0120 | Diabetes mellitus | [ICD-11: 5A10] | P31639 | SLC5A2 |
| T30085 | DI0175 | Heart failure | [ICD-11: BD10-BD1Z] | P31639 | SLC5A2 |
| T30085 | DI0417 | Type 2 diabetes mellitus | [ICD-11: 5A11] | P31639 | SLC5A2 |
| T64830 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P35346 | SSTR5 |
| T53024 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P30874 | SSTR2 |
| T53024 | DI0122 | Diagnostic imaging | [ICD-11: N.A.] | P30874 | SSTR2 |
| T53024 | DI0337 | Pituitary gland disorder | [ICD-11: 5A60-5A61] | P30874 | SSTR2 |
| T62974 | DI0087 | Chronic pain | [ICD-11: MG30] | P31391 | SSTR4 |
| T62974 | DI0179 | Hepatitis virus infection | [ICD-11: 1E50-1E51] | P31391 | SSTR4 |
| T16633 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P30872 | SSTR1 |
| T16633 | DI0395 | Stomach cancer | [ICD-11: 2B72] | P30872 | SSTR1 |
| T13644 | DI0108 | Cushing syndrome | [ICD-11: 5A70] | P32745 | SSTR3 |
| T72038 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | P17931 | LGALS3 |
| T72038 | DI0199 | Idiopathic interstitial pneumonitis | [ICD-11: CB03] | P17931 | LGALS3 |
| T72038 | DI0252 | Melanoma | [ICD-11: 2C30] | P17931 | LGALS3 |
| T72038 | DI0302 | Non-alcoholic fatty liver disease | [ICD-11: DB92] | P17931 | LGALS3 |
| T72038 | DI0351 | Psoriasis | [ICD-11: EA90] | P17931 | LGALS3 |
| T86918 | DI0110 | Cystic fibrosis | [ICD-11: CA25] | P04746 | AMY2A |
| T86918 | DI0328 | Pancreatic malfunction | [ICD-11: DC30-DC3Z] | P04746 | AMY2A |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |